Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synchrony Financial (SYF) vs 10X Genomics Inc (TXG) Price & Performance

Synchrony FinancialTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Synchrony Financial vs 10X Genomics Inc — how do they compare? Synchrony Financial trades at $79.16 (market cap $25.53B), while 10X Genomics Inc trades at $57.29 (market cap $7.61B). The key difference: Synchrony Financial is far larger — about 3.4× 10X Genomics Inc's market cap, and Synchrony Financial pays a 1.73% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

SYFTXG
Market Cap
$25.53B$7.61B
Sector
FinancialsHealth
52-Week High
$88.47$58.57
52-Week Low
$63.78$11.34
Dividend Yield
1.73%
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synchrony Financial

Synchrony Financial (SYF) trades at $78.78, up 0.75% today, with strong technical momentum as the stock tests resistance near $79. Recent earnings beats, including Q2 2026 EPS of $2.59 versus $2.14 expected, highlight robust fundamentals. The company maintains a net income margin of 23.4% and a low P/E of 8.05, signaling potential undervaluation. A new partnership with Stripe for CareCredit expansion and a $0.34 dividend reinforce positive business developments.

SYF presents a compelling investment case with analyst consensus bullish—62.5% buy ratings and an $86.33 price target imply ~10% upside. Risks include rising interest expenses of $4.14B and a projected negative net cash flow in 2026. Aggressive share buybacks and stable credit trends support upside, but macroeconomic pressures on consumer spending warrant monitoring.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG